Novartis has made a dramatic return to the Huntington's disease therapy stage by licensing a candidate from PTC Therapeutics ...

In its complaint, BMS alleges that HHS' Health Resources and Services Administration (HRSA), which has responsibility for ...

"A prerequisite for Orexo to succeed with a sophisticated digital health product like Deprexis is a tight collaboration with ...

Alligator – which has developing mitazalimab on its own after losing Johnson & Johnson as a partner for the drug a few years ...

Faced with a cash crunch, Alligator Biosciences has said it plans to shed up to 70% of its workforce and focus all its ...

Venture capital group Abingworth is reportedly trying to raise up to $1.5 billion in investment funding to support biopharma ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an increase in overall survival (OS) with the drug had reached statistical ...

A trade organisation representing pharma manufacturers in Europe has said plans to restrict the use of fluorinated substances known as PFAS could make manufacturing “grind to a halt” and ...

Nanoscope Therapeutics is on the brink of filing for FDA approval of what could be the first gene therapy for incurable eye disease retinitis pigmentosa (RP) that can be used regardless of ...

Artificial intelligence (AI) is poised to transform Medical Communications. From content creation to data analysis, AI has the potential to greatly enhance productivity and insights generation ...

Sanofi is paying $175 million upfront to claim a share of an experimental vaccine developed by Johnson & Johnson’s pharma unit Janssen that aims to tackle a major cause of blood infections.

Prilenia Therapeutics is planning to file its Huntington’s disease therapy pridopidine in the EU, despite mixed results in a phase 3 trial. Pridopidine is an oral agonist of the S1R protein ...